Teva Pharmaceutical Industries (TEVA) Finished Goods (2010 - 2018)

Teva Pharmaceutical Industries has disclosed Finished Goods across 9 years of filings, most recently posting $2.7 billion for Q4 2018.

• Quarterly Finished Goods fell 0.89% year-over-year to $2.7 billion in Q4 2018, while the trailing twelve-month figure through Dec 2018 was $2.7 billion (down 0.89% YoY) and the FY2018 annual result came in at $2.7 billion, down 0.89% from the prior year.
• Finished Goods retreated to $2.7 billion in Q4 2018, from $2.7 billion in the prior quarter.
• Over five years, Finished Goods peaked at $2.8 billion in Q4 2016 and troughed at $2.1 billion in Q4 2015.
• A 5-year average of $2.6 billion and a median of $2.7 billion in 2017 frame the typical range for Finished Goods.
• Annual changes were most pronounced in 2014 — Finished Goods retreated 11.65% — and 2016, when it surged 38.15%.
• Tracing TEVA's Finished Goods over 5 years: stood at $2.3 billion in 2014, then slipped by 9.61% to $2.1 billion in 2015, then surged by 38.15% to $2.8 billion in 2016, then decreased by 5.05% to $2.7 billion in 2017, then slipped by 0.89% to $2.7 billion in 2018.
• Business Quant data shows TEVA's Finished Goods at $2.7 billion in Q4 2018, $2.7 billion in Q3 2018, and $2.7 billion in Q2 2018.